Shen-yuan-dan capsule inhibits METTL3-mediated m6A methylation to restore autophagy homeostasis and attenuate post-myocardial infarction heart failure

Heart failure (HF) after myocardial infarction (MI) is a serious health issue. This study investigates the therapeutic effects of Shen-Yuan-Dan Capsule (SYD) on post-MI HF and explores its mechanisms, particularly involving m6A modification and autophagy. Using network pharmacology and MeRIP-seq, we identified potential epitranscriptomic targets. In vitro, H9c2 cardiomyocytes were treated with Phenylephrine (PE) and SYD. MeRIP-seq analysis identified differential m6A peak distribution among control, PE-induced, and SYD-treated groups, revealing that SYD alleviates HF by regulating the mTOR/TFEB autophagy pathway through inhibition of METTL3-mediated m6A modification.